Close menu




August 18th, 2022 | 10:21 CEST

Sell Nel ASA? Buy HelloFresh and Aspermont?

  • Technology
  • Media
  • Fintech
Photo credits: pixabay.com

Despite individual setbacks, the mood on the stock market is currently good and the summer rally is underway. Alongside shares from the technology sector, hydrogen stocks such as Plug Power and Nel ASA are currently among the high flyers. However, JPMorgan is interfering. The analysts rate the hydrogen specialist as "Underweight" and thus advise selling. They believe the share price could drop by a significant double-digit percentage. In contrast, two analysts have commented positively on HelloFresh. Berenberg even sees a doubling potential. There are also praising words for Aspermont. The debt-free Company is growing, the new fintech platform is exciting, and the valuation is very low compared to the peer group.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: NEL ASA NK-_20 | NO0010081235 , HELLOFRESH SE INH O.N. | DE000A161408 , ASPERMONT LTD | AU000000ASP3

Table of contents:


    Fan Xian Yong, CEO, The Place Holdings
    "[...] We recognized that there is a lack of business models that combine innovative business concepts, such as "new retail" solutions and omni-channel strategies, with conventional business segments. [...]" Fan Xian Yong, CEO, The Place Holdings

    Full interview

     

    Aspermont: Forecasts for 2022 and 2023 too low?

    For the experts at researchanalyst.com, the Aspermont share should be heading for old highs on the back of the new fintech platform. After the successful transformation from a venerable publishing house to a digital B2B media house for the global commodities sector, the Australian Company would be back on track for expansion. Aspermont is debt-free and continues to grow unabated. In addition to the existing divisions, the reopening of live events after the Corona pandemic should still show up in the upcoming third-quarter numbers in early September. Given the growing business, experts would not be surprised to see Aspermont raise its guidance for fiscal 2022 and 2023 soon.

    With the launch of the Blu Horseshoe placement platform - where customers are given access to the lucrative secondary issuance market on the Australian stock exchange ASX - the Australians have also succeeded in entering the huge fintech business. The modular and highly scalable platform should also see more projects such as "Resource Stocks" or the "Content" work platform launch in the near future, which could further increase both the number and value of the customer. Aspermont is currently valued at just USD 36.97 million. The financing platform alone is worth more. London-based placement platform PimaryBid, for example, recently raised a funding round on a post valuation of a whopping USD 690 million. Among the big-name investors was the global private equity giant SoftBank. While Blu Horseshoe and PrimaryBid are at different stages, the potential is clearly demonstrated in these digital scaling monsters. Click here to read the full study.

    Nel ASA: Plenty of growth imagination, but no bargain

    researchanalyst.com had also commented on Nel following the quarterly figures (to the report). Despite all rosy perspectives, the Norwegians with a price-sales ratio of over 20 are anything but cheap. Despite the recent doubling of the share price, Plug Power has a sales ratio of 16, which means that Nel is certainly not a bargain. JPMorgan expresses it even more drastically. In the second quarter, Nel's sales and EBITDA missed expectations. Therefore, the analysts reduced their estimates for 2022, 23 and 24. The price target for the shares of the hydrogen specialist was also reduced from NOK 11.10 to NOK 10.10. Currently, the Nel share is quoted at around NOK 15.70. In addition, it was also announced yesterday that Nel has divested its stake in Nikola worth USD 7.5 million. The pre-IPO investment in the start-up, which specializes in electric trucks, still generated a profit of USD 2.5 million for Nel. Nel also announced that it increased its capital by 4.4 million shares as part of an employee stock ownership program.

    HelloFresh share: EUR 60 or only EUR 27?

    The HelloFresh share has not yet been able to benefit from the tech rally of recent weeks. And yesterday, too, the DAX member went down quite significantly. Yet analysts have recently been largely optimistic for the provider of cooking boxes. Following the publication of the final quarterly figures, Berenberg renewed its buy recommendation. The Company has the effects of rising inflation under control, and the discounts are also stable. Therefore, the analysts see a price target of EUR 60. Barclays is somewhat more cautious, but even their price target of EUR 44 would mean an increase of almost 50%. The current concern would be that growth in other international sales markets could not keep pace with the US market. Only Bernstein Research, with its price target of EUR 27, sees no upside potential for the HelloFresh share at the moment. The bad news has been worked off in the meantime, but customer demand remains weak. The analysts recommend that HelloFresh focuses on affluent customers with a somewhat high pricing policy. That would strengthen profitability.


    The long-term opportunities in the hydrogen sector are huge, but so are the valuations. At Nel, the operating business has yet to grow into the valuation. At Aspermont, this appears to be more the other way around, and the outlook is also right. According to the majority of analysts, the HelloFresh share has catch-up potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Armin Schulz on October 4th, 2022 | 10:58 CEST

    JinkoSolar, TubeSolar, Encavis - Shares for the energy turnaround

    • agritech
    • renewableenergies
    • Technology

    The phase-out of fossil energy generation is a done deal in Germany, but there is still a long way to go. Germany's share of renewable energies in electricity generation was 42.4% in 2021. However, this covered only 19.7% of Germany's energy consumption. Since the flare-up of the Ukraine crisis, the expansion of renewable energies is to be accelerated. A balanced mix is essential. Spring and summer are the main times for solar power, while in fall and winter, when the days are shorter, wind power is the primary source of electricity. If we want to achieve the 2030 targets, a massive expansion is essential. Today we take a look at three renewable energy companies.

    Read

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read